Are we in need of NEDA?

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.

Multiple sclerosis and related disorders·2026

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026

Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).

Clinical biochemistry·2026

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025

Subvoxel quantitative susceptibility mapping reveals distinct susceptibility patterns and clinical associations of juxtacortical paramagnetic rims in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Effectiveness of the recombinant zoster vaccine in adult patients with multiple sclerosis: A claims-based retrospective cohort study in the United States.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Gynecologic complications of disease-modifying therapy in women with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Emergency department use before multiple sclerosis: Presenting complaints and discharge diagnoses.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Colorectal cancer screening in individuals with multiple sclerosis: A mixed-methods study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Increased exertion variability is linked to disruptions in effort assessment in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Porcine coronavirus promotes NLRP3 inflammasome activation during virus-induced neuroinflammation.

mBio·2026

Patterns of Neurological Recovery after Posterior Decompression Without Fusion for Degenerative Cervical Myelopathy According to the Timing of Minimum Clinically Important Difference Achievement.

Global spine journal·2026

Management Patterns and Outcomes of Vestibular Schwannoma in Older Adults: Assessment of the SEER Database.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026

Paeonol as a Multi-Target Therapy for Neurological Disorders: Mechanistic Insights Into Neuroprotection.

Immunity, inflammation and disease·2026

Combined Vitamin D and Resveratrol Treatment Attenuates Motor Deficits and Neurodegeneration in a 6-OHDA Mouse Model of Parkinson's Disease in Male Mice: A Focus on Sirt1 and Lingo-1 Pathways in the Ventral Tegmental Area.

Brain and behavior·2026

Unraveling the Inflammatory Enigma: Is Neuroinflammation a Culprit or Consequence in Pharmacoresistant Epilepsy?

Brain and behavior·2026

Related Experiment Videos

Are we in need of NEDA?

Related Concept Videos

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Subvoxel quantitative susceptibility mapping reveals distinct susceptibility patterns and clinical associations of juxtacortical paramagnetic rims in multiple sclerosis.

Effectiveness of the recombinant zoster vaccine in adult patients with multiple sclerosis: A claims-based retrospective cohort study in the United States.

Gynecologic complications of disease-modifying therapy in women with multiple sclerosis.

Emergency department use before multiple sclerosis: Presenting complaints and discharge diagnoses.

Colorectal cancer screening in individuals with multiple sclerosis: A mixed-methods study.

Increased exertion variability is linked to disruptions in effort assessment in multiple sclerosis.

Porcine coronavirus promotes NLRP3 inflammasome activation during virus-induced neuroinflammation.

Patterns of Neurological Recovery after Posterior Decompression Without Fusion for Degenerative Cervical Myelopathy According to the Timing of Minimum Clinically Important Difference Achievement.

Management Patterns and Outcomes of Vestibular Schwannoma in Older Adults: Assessment of the SEER Database.

Paeonol as a Multi-Target Therapy for Neurological Disorders: Mechanistic Insights Into Neuroprotection.

Combined Vitamin D and Resveratrol Treatment Attenuates Motor Deficits and Neurodegeneration in a 6-OHDA Mouse Model of Parkinson's Disease in Male Mice: A Focus on Sirt1 and Lingo-1 Pathways in the Ventral Tegmental Area.

Unraveling the Inflammatory Enigma: Is Neuroinflammation a Culprit or Consequence in Pharmacoresistant Epilepsy?

Related Experiment Videos

Are we in need of NEDA?

Related Concept Videos

Related Articles